Defective proteins found to be potential targets for Alzheimer’s treatments
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
List view / Grid view
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.
Researchers in Japan propose that the antimalarial drug mefloquine could be repurposed to effectively treat SARS-CoV-2.
Drug analysis at the Francis Crick Institute and University of Dundee has revealed 15 potential antivirals that could lead to new COVID-19 treatments.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
Researchers have explored the interaction between SARS-CoV-2 RNA and the host cell, uncovering possible targets to prevent viral replication.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.